John Strickler, MD
Medical Oncology · Durham, NCNPI 1265523377
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $260,907 of the $319,115 with a category attached, or 81.8%. It is spread thinly across 36 manufacturers, the largest accounting for just 19.0%. Among medical oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $1246.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$60K
- AbbVie$59K
- Seagen Inc.$24K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- Pfizer$17K
- Regeneron$16K
- plus $124K from 30 others
Across 1,671 payments — averaging $13,907 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$13.3M
- AbbVie$3.5M
- Seagen Inc.$1.9M
- Genentech, Inc.$1.4M
- Pfizer$691K
- Beigene, Ltd.$496K
- plus $1.9M from 11 others
What the payments were for
- Consulting fees$260,90782%
- Speaking & faculty fees$18,1666%
- Travel & lodging$35,01311%
- Food & beverage$4,9622%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 46 | $60,498 |
| AbbVie | 43 | $59,077 |
| Seagen Inc. | 19 | $24,478 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $18,670 |
| Pfizer | 14 | $16,906 |
| Regeneron | 18 | $15,815 |
| Janssen Research & Development, LLC | 9 | $12,391 |
| Merck | 16 | $11,797 |
| F. Hoffmann-la Roche AG | 5 | $10,907 |
| Exelixis Inc. | 9 | $7,712 |
| GSK | 7 | $7,362 |
| Array Biopharma Inc | 3 | $7,234 |
| Incyte Corporation | 10 | $6,525 |
| E.r. Squibb & Sons, L.L.C. | 3 | $5,933 |
| Sanofi US Services Inc. | 1 | $5,311 |
| Ipsen Biopharmaceuticals, Inc | 5 | $5,267 |
| Astellas Pharma Global Development | 2 | $4,445 |
| Daiichi Sankyo Inc. | 3 | $4,080 |
| Mylan Inc. | 1 | $3,920 |
| Amgen | 2 | $3,798 |
| Taiho Oncology, Inc. | 3 | $3,704 |
| AstraZeneca | 2 | $3,560 |
| Boehringer Ingelheim | 1 | $3,045 |
| GE HealthCare | 2 | $2,832 |
| Jazz Pharmaceuticals Inc. | 1 | $2,730 |
| Beigene USA, Inc. | 1 | $2,625 |
| Eli Lilly | 4 | $2,245 |
| Janssen Scientific Affairs, LLC | 1 | $2,025 |
| Astrazeneca UK Limited | 1 | $1,343 |
| Hoffmann-la Roche Limited | 4 | $939 |
| Lilly USA, LLC | 1 | $800 |
| Astellas Pharma Inc | 3 | $754 |
| Genentech USA, Inc. | 1 | $125 |
| Intera Oncology, Inc | 1 | $123 |
| Astellas Pharma Europe Ltd | 2 | $79 |
| Genentech, Inc. | 1 | $63 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$319,115 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metronidazole | 13 | $1,334 |
| Prochlorperazine Maleate | 25 | $581 |
| Dexamethasone | 35 | $571 |
| Ondansetron Hcl | 29 | $301 |
| Olanzapine | 14 | $278 |
| Minocycline Hcl | 13 | $209 |
| Oxycodone Hcl | 22 | $209 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $179 |
| Potassium Chloride | 20 | $122 |
| Amlodipine Besylate | 11 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $800 | $27814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 medical oncology providers in North Carolina.
Other medical oncology in Durham
- Thomas LeblancDurham$1.7M
- Andrew ArmstrongDurham$377K
- Neal ReadyDurham$309K
- Michael HarrisonDurham$161K
- Jeffrey ClarkeDurham$140K
- Sundhar RamalingamDurham$93K
- Arif KamalDurham$50K
- Nelson ChaoDurham$45K
- Laura AlderDurham$34K
- Kaushik SenDurham$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.